NUTEX Investments (BUD:NUTEX) EBIT: Ft-108.44 Mil (TTM As of Dec. 2025)


BUD:NUTEX NUTEX Investments PLC BUD:NUTEX
50 GF Score
Price Ft13.40
GF Value Ft13.80
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is NUTEX Investments EBIT?

NUTEX Investments BUD:NUTEX -0.37% 50 EBIT is Ft-108.44 Mil as of Dec. 2025. GuruFocus rates BUD:NUTEX with a GF Score™ of 50/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review.

NUTEX Investments's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was Ft-238.79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was Ft-108.44 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NUTEX Investments's annualized ROC % for the quarter that ended in Dec. 2025 was 20.76%. NUTEX Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -10,841.86%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NUTEX Investments's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 2.99%.


NUTEX Investments  (BUD:NUTEX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NUTEX Investments's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=40.088 * ( 1 - 8.22% )/( (203.906 + 150.498)/ 2 )
=36.7927664/177.202
=20.76 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5203.841 - 1.557 - ( 4998.378 - max(0, 16.791 - 5195.254+4998.378))
=203.906

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5555.28 - 26.868 - ( 5377.914 - max(0, 35.718 - 5555.057+5377.914))
=150.498

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

NUTEX Investments's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-477.584/( ( (8.587 + max(-16.566, 0)) + (0.223 + max(-37.213, 0)) )/ 2 )
=-477.584/( ( 8.587 + 0.223 )/ 2 )
=-477.584/4.405
=-10,841.86 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.22500000000036) - (1.557 + 0 + 15.234)
=-16.566

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + -1.4949999999999) - (26.868 + 0 + 8.85)
=-37.213

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NUTEX Investments's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-108.44/-3631.204
=2.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NUTEX Investments EBIT Related Terms


NUTEX Investments EBIT Historical Data

* Premium members only.

The historical data trend for NUTEX Investments's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NUTEX Investments EBIT Chart

NUTEX Investments Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.99 142.65 426.36 -96.67 -108.44

NUTEX Investments Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 451.13 267.94 -364.61 130.35 -238.79

BUD:NUTEX vs ZTS, UTHR, VTRS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NUTEX Investments EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NUTEX Investments's EV-to-EBIT falls into.


BUD:NUTEX
50GF Score
NUTEX Investments PLC BUD:NUTEX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NUTEX Investments EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was Ft-108.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of Ft-108.44 Mil mean?
NUTEX Investments (BUD:NUTEX) has a EBIT of Ft-108.44 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NUTEX Investments.
Is NUTEX Investments' EBIT too high?
NUTEX Investments' current EBIT is Ft-108.44 Mil. Overall, NUTEX Investments has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' EBIT compare to ZTS and UTHR?
NUTEX Investments' EBIT of Ft-108.44 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NUTEX Investments. NUTEX Investments's current EBIT is Ft-108.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft13.40 — trading 2.9% below its estimated fair value. The current EBIT is Ft-108.44 Mil. NUTEX Investments' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current EBIT is Ft-108.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?

Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued. The current stock price of Ft13.40 is trading 2.9% below its estimated GF Value™ of Ft13.80. GuruFocus considers NUTEX Investments to be Fairly Valued.

Key valuation signals for BUD:NUTEX:

  • EBIT: Ft-108.44 Mil
  • GF Value™: Ft13.80 vs. price of Ft13.40 (2.9% below fair value)
  • GF Score™: 50/100 with 3 warning signs

No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NUTEX Investments Business Description

Address Telepes u. 53., Budapest, HUN, 1147
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
50GF Score

Get the complete analysis for BUD:NUTEX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

Ft13.40
Price
Ft13.80
GF Value